more than 10 clinical studies using radiostrontium ( sr-89 ) have shown benefit in about 70-80 % of patients having refractory bone pain from prostate , breast and other metastatic bone cancers , with minimal hematological toxicity .
C0262950
bone
C0153690
metastatic bone cancers